Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatological conditions.
BioFocus will apply its screening technologies and compound collections to an undisclosed number of Almirall projects.
Almirall R&D executive director CSO Bertil Lindmark said they have been impressed by the depth of the BioFocus technology platforms, the size, content and diversity of the available compound decks and the obvious strength and experience of the scientists that will be engaged on their projects.